endometrial cancer

  •   George Lundberg, MD

    This 2022 scientific review article from the Journal of the Advanced Practitioner in Oncology discusses new treatment options for people with advanced endometrial cancer.

    .

  •   George Lundberg, MD

    Molecular testing often guides choices of immunotherapy, as illustrated in this OncLive story about endometrial cancer.

    .

  •   George Lundberg, MD

    The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.

    .

  •   George Lundberg, MD

    Article from The ASCO Post curated by Contributing Editor George Lundberg, MD, who notes: 

    Recent clinical trial results show that immunotherapy—a type of treatment that boosts the immune system to fight cancer—provided long-lasting, improved outcomes for patients with advanced cervical or endometrial cancer. These are important findings for difficult-to-treat cancers.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    There are two principal forms of uterine cancer: cervical and endometrial. Endometrial carcinoma is the most frequent cancer of the female genitalia in the developed world, with about 3% of U.S. women likely to receive such a diagnosis. This 2018 review from Medscape is comprehensive.